DE69905392T2 - Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid - Google Patents

Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid

Info

Publication number
DE69905392T2
DE69905392T2 DE69905392T DE69905392T DE69905392T2 DE 69905392 T2 DE69905392 T2 DE 69905392T2 DE 69905392 T DE69905392 T DE 69905392T DE 69905392 T DE69905392 T DE 69905392T DE 69905392 T2 DE69905392 T2 DE 69905392T2
Authority
DE
Germany
Prior art keywords
agent
pharmaceutical composition
peptide
antique
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69905392T
Other languages
English (en)
Other versions
DE69905392D1 (de
Inventor
Jamal Temsamani
Michel Kaczorek
De Verdiere Annik Colin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synt EM SA
Original Assignee
Synt EM SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synt EM SA filed Critical Synt EM SA
Publication of DE69905392D1 publication Critical patent/DE69905392D1/de
Application granted granted Critical
Publication of DE69905392T2 publication Critical patent/DE69905392T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69905392T 1998-11-30 1999-11-26 Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid Expired - Lifetime DE69905392T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9815073A FR2786398B1 (fr) 1998-11-30 1998-11-30 Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
PCT/FR1999/002939 WO2000032237A1 (fr) 1998-11-30 1999-11-26 Composition pharmaceutique comprenant un agent anti-cancereux et au moins un peptide

Publications (2)

Publication Number Publication Date
DE69905392D1 DE69905392D1 (de) 2003-03-20
DE69905392T2 true DE69905392T2 (de) 2003-10-09

Family

ID=9533369

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69905392T Expired - Lifetime DE69905392T2 (de) 1998-11-30 1999-11-26 Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid

Country Status (13)

Country Link
US (1) US7527792B1 (de)
EP (1) EP1135169B1 (de)
JP (1) JP2002538080A (de)
AT (1) ATE232398T1 (de)
AU (1) AU769766B2 (de)
CA (1) CA2352134A1 (de)
DE (1) DE69905392T2 (de)
DK (1) DK1135169T3 (de)
ES (1) ES2192420T3 (de)
FR (1) FR2786398B1 (de)
IL (2) IL143012A0 (de)
PT (1) PT1135169E (de)
WO (1) WO2000032237A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
FR2821272B1 (fr) * 2001-02-23 2004-12-17 Synt Em Composes constitues d'une molecule analgesique liee a un vecteur capable de vectoriser ladite molecule a travers la barriere hematoencephalique et compositions pharmaceutiques les contenant
FR2830016B1 (fr) * 2001-09-27 2004-06-25 Synt Em Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau
US7314626B2 (en) 2001-10-16 2008-01-01 Synt:Em S.A. Use of peptide vectors to improve the immune response to antigens
FR2840810B1 (fr) * 2002-06-18 2005-02-11 Synt Em Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
US11564991B2 (en) 2014-11-12 2023-01-31 University Of Mississippi Medical Center Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability
WO2016077618A1 (en) * 2014-11-12 2016-05-19 University Of Mississippi Medical Center Kidney-targeted drug delivery systems
KR102015524B1 (ko) * 2016-12-26 2019-08-29 인터올리고 주식회사 압타머-약물 콘쥬게이트 및 그 용도
US11248038B2 (en) 2019-03-29 2022-02-15 University Of Mississippi Medical Center Molecular-size of elastin-like polypeptide delivery system for therapeutics modulates intrarenal deposition and bioavailability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
BR9808863A (pt) * 1997-04-14 2001-09-18 Univ California Composições antiestrogênicas peptìdicas e métodos para tratar câncer de mama
FR2767323B1 (fr) * 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
FR2830016B1 (fr) 2001-09-27 2004-06-25 Synt Em Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau

Also Published As

Publication number Publication date
DE69905392D1 (de) 2003-03-20
IL143012A0 (en) 2002-04-21
ATE232398T1 (de) 2003-02-15
AU1391100A (en) 2000-06-19
WO2000032237A1 (fr) 2000-06-08
DK1135169T3 (da) 2003-06-10
FR2786398A1 (fr) 2000-06-02
JP2002538080A (ja) 2002-11-12
AU769766B2 (en) 2004-02-05
CA2352134A1 (fr) 2000-06-08
FR2786398B1 (fr) 2002-12-27
PT1135169E (pt) 2003-06-30
EP1135169A1 (de) 2001-09-26
US7527792B1 (en) 2009-05-05
IL143012A (en) 2007-05-15
ES2192420T3 (es) 2003-10-01
EP1135169B1 (de) 2003-02-12

Similar Documents

Publication Publication Date Title
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
ATE208382T1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
BR9607260A (pt) Utilização de aerogéis em agricultura
DE69912870D1 (de) Kosmetische oder dermatologische Zusammensetzung, enthaltend zumindest ein natürliches oder rekombinantes Seidenprotein von Arachniden oder ein analoges Protein
BG103664A (en) Pharmaceutical forms containing ammoxycillin and clavulanate
DE69710065D1 (de) Androsten-derivate
MX9702170A (es) Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres.
NO934706L (no) Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
DE69905392D1 (de) Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid
IL141686A0 (en) Methods of treating hypertension and compositions for use therein
ATE253820T1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
KR100292396B1 (de)
SE9802937D0 (sv) Novel compounds
MX9601151A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento de liquenes y prurito y composicion obtenida.
DE69606321T2 (de) Stabilisiertes sonnenschutzmittel
WO1999021574A3 (en) Enhancement of morphogen activity
FR2687162B1 (fr) Pigments a l'etat de tablettes, leur preparation et leurs utilisations.
ATE417926T1 (de) Zusammensetzungen zur modulierung der länge von telomeren
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
ATE390921T1 (de) Zusammensetzung mit demethylcantharidin in kombination mit platinhaltigen antikrebsmitteln und ihre verwendung
EP0970688A3 (de) Verwendung von Eisen-Titan-Mischoxiden zur Verstärkung der Lichtschutzleistung kosmetischer oder dermatologischer Lichtschutzmittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition